Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is a Healthcare company (Biotechnology) with a market capitalization of $9.8B. The Maz Rating grades it against the other companies in its sector.
Madrigal Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $421.99, Madrigal Pharmaceuticals, Inc. trades at 6.9x sales and 19.7x book value. Over the last twelve months it generated about $1.4B of revenue and a net loss of $137M. It runs a gross margin of 91.0%, an operating margin of -10.7% and a net margin of -10.9%. It shows return on equity of -27.1%, return on invested capital of -15.6% and a free cash flow yield of -1.7%. On the balance sheet: a debt-to-equity ratio of 0.56 and a current ratio of 3.05. Over the past 52 weeks the share price ranged from $353.54 to $615.00, with a beta of -1.00.
Madrigal Pharmaceuticals, Inc. does not currently pay a dividend.
25 Wall Street analyst ratings cover the stock: 22 Buy, 2 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Madrigal Pharmaceuticals, Inc. (MDGL) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.42% / 30% · (Cash+Inv) / Mkt Cap (36m) 6.83% / 30% · Interest income / Revenue 1.91% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 2.42% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 6.83% / 33% · Receivables / Mkt Cap (36m) 1.62% / 49% · Interest income / Revenue 1.91% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 2.42% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 6.83% / 33.33% · Receivables / Mkt Cap (24m) 1.62% / 33.33% · Interest income / Revenue 1.91% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 26.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 69.7% / 33.33% · Receivables / Avg Assets (4Q) 14.4% / 33.33% · Interest income / Revenue 1.91% / 5% | Fail |
| FTSE | Debt / Total Assets 23.8% / 33.33% · (Cash+ST Inv) / Total Assets 67.0% / 33.33% · (Cash+Recv) / Total Assets 82.8% / 33.33% · Interest income / Revenue 1.91% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Madrigal Pharmaceuticals, Inc. (MDGL) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Madrigal Pharmaceuticals, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.91% of each dividend: Madrigal Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.